Lafora disease — from pathogenesis to treatment strategies

Felix Nitschke, Saija J. Ahonen, Silvia Nitschke, Sharmistha Mitra, Berge A. Minassian

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Lafora disease is a severe, autosomal recessive, progressive myoclonus epilepsy. The disease usually manifests in previously healthy adolescents, and death commonly occurs within 10 years of symptom onset. Lafora disease is caused by loss-of-function mutations in EPM2A or NHLRC1, which encode laforin and malin, respectively. The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies. Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease. The integration of current knowledge on the function of laforin–malin as an interacting complex suggests that laforin recruits malin to parts of glycogen molecules where overly long glucose chains are forming, so as to counteract further chain extension. In the absence of either laforin or malin function, long glucose chains in specific glycogen molecules extrude water, form double helices and drive precipitation of those molecules, which over time accumulate into Lafora bodies. In this article, we review the genetic, clinical, pathological and molecular aspects of Lafora disease. We also discuss traditional antiseizure treatments for this condition, as well as exciting therapeutic advances based on the downregulation of brain glycogen synthesis and disease gene replacement.

Original languageEnglish (US)
Pages (from-to)606-617
Number of pages12
JournalNature Reviews Neurology
Volume14
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Lafora Disease
Glycogen
Progressive Myoclonic Epilepsy
Glucose
Genetic Models
Therapeutics
Down-Regulation
Mutation
Water
Brain
Genes
Proteins

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Lafora disease — from pathogenesis to treatment strategies. / Nitschke, Felix; Ahonen, Saija J.; Nitschke, Silvia; Mitra, Sharmistha; Minassian, Berge A.

In: Nature Reviews Neurology, Vol. 14, No. 10, 01.10.2018, p. 606-617.

Research output: Contribution to journalReview article

Nitschke, Felix ; Ahonen, Saija J. ; Nitschke, Silvia ; Mitra, Sharmistha ; Minassian, Berge A. / Lafora disease — from pathogenesis to treatment strategies. In: Nature Reviews Neurology. 2018 ; Vol. 14, No. 10. pp. 606-617.
@article{e6434865b3764e5490986057ea1855a5,
title = "Lafora disease — from pathogenesis to treatment strategies",
abstract = "Lafora disease is a severe, autosomal recessive, progressive myoclonus epilepsy. The disease usually manifests in previously healthy adolescents, and death commonly occurs within 10 years of symptom onset. Lafora disease is caused by loss-of-function mutations in EPM2A or NHLRC1, which encode laforin and malin, respectively. The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies. Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease. The integration of current knowledge on the function of laforin–malin as an interacting complex suggests that laforin recruits malin to parts of glycogen molecules where overly long glucose chains are forming, so as to counteract further chain extension. In the absence of either laforin or malin function, long glucose chains in specific glycogen molecules extrude water, form double helices and drive precipitation of those molecules, which over time accumulate into Lafora bodies. In this article, we review the genetic, clinical, pathological and molecular aspects of Lafora disease. We also discuss traditional antiseizure treatments for this condition, as well as exciting therapeutic advances based on the downregulation of brain glycogen synthesis and disease gene replacement.",
author = "Felix Nitschke and Ahonen, {Saija J.} and Silvia Nitschke and Sharmistha Mitra and Minassian, {Berge A.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1038/s41582-018-0057-0",
language = "English (US)",
volume = "14",
pages = "606--617",
journal = "Nature Reviews Neurology",
issn = "1759-4758",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Lafora disease — from pathogenesis to treatment strategies

AU - Nitschke, Felix

AU - Ahonen, Saija J.

AU - Nitschke, Silvia

AU - Mitra, Sharmistha

AU - Minassian, Berge A.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Lafora disease is a severe, autosomal recessive, progressive myoclonus epilepsy. The disease usually manifests in previously healthy adolescents, and death commonly occurs within 10 years of symptom onset. Lafora disease is caused by loss-of-function mutations in EPM2A or NHLRC1, which encode laforin and malin, respectively. The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies. Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease. The integration of current knowledge on the function of laforin–malin as an interacting complex suggests that laforin recruits malin to parts of glycogen molecules where overly long glucose chains are forming, so as to counteract further chain extension. In the absence of either laforin or malin function, long glucose chains in specific glycogen molecules extrude water, form double helices and drive precipitation of those molecules, which over time accumulate into Lafora bodies. In this article, we review the genetic, clinical, pathological and molecular aspects of Lafora disease. We also discuss traditional antiseizure treatments for this condition, as well as exciting therapeutic advances based on the downregulation of brain glycogen synthesis and disease gene replacement.

AB - Lafora disease is a severe, autosomal recessive, progressive myoclonus epilepsy. The disease usually manifests in previously healthy adolescents, and death commonly occurs within 10 years of symptom onset. Lafora disease is caused by loss-of-function mutations in EPM2A or NHLRC1, which encode laforin and malin, respectively. The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies. Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease. The integration of current knowledge on the function of laforin–malin as an interacting complex suggests that laforin recruits malin to parts of glycogen molecules where overly long glucose chains are forming, so as to counteract further chain extension. In the absence of either laforin or malin function, long glucose chains in specific glycogen molecules extrude water, form double helices and drive precipitation of those molecules, which over time accumulate into Lafora bodies. In this article, we review the genetic, clinical, pathological and molecular aspects of Lafora disease. We also discuss traditional antiseizure treatments for this condition, as well as exciting therapeutic advances based on the downregulation of brain glycogen synthesis and disease gene replacement.

UR - http://www.scopus.com/inward/record.url?scp=85052962451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052962451&partnerID=8YFLogxK

U2 - 10.1038/s41582-018-0057-0

DO - 10.1038/s41582-018-0057-0

M3 - Review article

C2 - 30143794

AN - SCOPUS:85052962451

VL - 14

SP - 606

EP - 617

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

SN - 1759-4758

IS - 10

ER -